In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation.
They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease.
To learn more about the topics in this episode:
-
With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest
-
Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug
-
Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation
-
Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline
-
Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active